Preferred Label : Modified Aldesleukin/Palivizumab Fusion Protein IOV-3001;
NCIt synonyms : Modified Interleukin-2 Fusion Protein IOV-3001; Modified IL-2 Fusion Protein IOV-3001; Modified Dimeric IL-2/Antibody Fusion Protein IOV-3001;
NCIt definition : A fusion protein composed of a modified form of the recombinant interleukin-2 (IL-2)
aldesleukin incorporated into the antibody palivizumab, with potential immunostimulating
and antineoplastic activities. Upon administration of modified aldesleukin/palivizumab
fusion protein IOV-3001, the modified aldesleukin moiety targets and binds to the
IL-2 receptor (IL-2R) and activates IL-2/IL-2R-mediated signaling. This activates
cytotoxic T-lymphocytes (CTLs) and natural killer (NK) cells, and induces expression
of certain cytotoxic cytokines, such as interferon-gamma (IFNg) and transforming growth
factor-beta (TGFb), which enhances T-cell-mediated cytotoxic immune responses against
tumor cells. The incorporation of aldesleukin into palivizumab increases the half-life
of IOV-3001.;
Molecule name : IOV 3001; IOV-3001;
Origin ID : C219035;
concept_is_in_subset
